80 results about "Lacceroic acid" patented technology

The application discloses a composition with long-acting anti-wrinkle, skin elasticity improvement and skin tightening effects, a preparation method and application thereof, and belongs to the technical field of cosmetics. The composition comprises the following efficacy components: Schizosaccharomyces pombe ferment lysate, hydroxypropyl tetrahydropyrane triol, lactose, whey protein, lactic acid, Lactarius volemus extract and palm leaf tree extract. The eye cream prepared by using the composition has very significant long-acting anti-wrinkle, skin elasticity improvement and skin tightening effects. After 28 days of use, the R2 value of skin elasticity at the corner of the eye is increased by more than 20%, the R0 value of total skin stretching displacement is decreased by more than 40%, the proportion of wrinkle area is decreased by more than 15%, and the wrinkle depth is decreased by more than 27%. The effect after 28 days of use is also significantly better than that after 14 days of use.

This invention proposes a combined inhibitor for separating bastnaesite and monazite, along with its method and application. The raw materials for the combined inhibitor include small organic molecules and microbial polysaccharides; the small organic molecules include one or more of oxalic acid, malic acid, tartaric acid, lactic acid, succinic acid, and citric acid; the microbial polysaccharides include one or more of currant gum, guar gum, xanthan gum, and gellan gum. This invention achieves highly selective inhibition of monazite on the mineral surface through the synergistic adsorption and action of the inhibitor, with small organic molecules and microbial polysaccharides as the main components, thereby efficiently separating bastnaesite under mild flotation conditions. It offers advantages such as good selectivity, strong action, low reagent cost, and environmental friendliness.

This invention provides a physiological age prediction model that predicts the physiological age of a subject by detecting urinary proteins and metabolites in a urine sample. The aforementioned urinary proteins and metabolites are those that change significantly with age, including one or more selected from the following: cartilage intermediate layer protein (CILP2), collagen Alpha 1 chain (COFA1), myristic acid, 12-methyltridecanoic acid, CN family member 5 (CCN5), Sushi domain-containing protein 5 (SUSD5), procollagen C endopeptidase enhancer 1 (PCOLCE), and L-lactate oxidase (LOX), preferably including all of the aforementioned urinary proteins and metabolites.

The application discloses a kind of high adhesion hydrogel for electroencephalogram test and its preparation method and application, belong to biomedical engineering technical field.The hydrogel includes the following components crosslinked product: anionic monomer, cationic monomer, monomer and mutual penetration agent;The anionic monomer is any one of malic acid, gluconic acid, citric acid and lactic acid, cationic monomer is betaine or acetyl L-carnitine, monomer is N, N-dimethyl acrylamide, acrylic acid, sodium acrylate, 4-acryloyl morpholine or sodium acrylamidomethyl propane sulfonate, mutual penetration agent is sodium chloride aqueous solution or sodium chloride water-retaining agent solution.Preparation, cationic monomer is mixed and dissolved, vacuum drying, adding photo initiator mixing, then mutual penetration agent is added, and it is obtained by ultraviolet light crosslinking.The hydrogel of the application has high adhesion (adhesion strength reaches 203.22 kPa), high ion mobility and excellent biocompatibility, and the signal gain in EEG and ECG test reaches 2-3 times of traditional conductive paste, which can be widely used in medical conductive paste field.

The application provides a long-acting external use efinaconazole composition, a preparation method and application, and belongs to the technical field of pharmaceutical compositions.The long-acting external use efinaconazole composition comprises the following components in percentage by weight: efinaconazole 0.5-3%, a film forming agent 3-7%, a gel agent 2-3%, a plasticizer 3-7%, a cosolvent 0.78-1.56% and a solvent in a residual amount.The application forms a eutectic mixture of efinaconazole and lactic acid, improves the solubility and permeability of the active ingredient, dissolves in the solvent of an ethanol system, and adds the film forming agent and the plasticizer, so that a drug depot is formed on the surface of the skin through the film forming principle, the drug is released slowly, the clinical compliance is improved, the frequency of drug administration is reduced, the bioavailability of the drug in the stratum corneum is increased, the effectiveness and safety of the drug can be improved, the basic theory of pharmacoeconomics is met, and the clinical value of the product is improved.

Fabric care compositions and, preferably, fabric care compositions adapted to reduce and / or remove malodor from a fabric are disclosed herein. In accordance with an aspect of the invention, provided is a fabric care composition including from about 3 to about 8.5 wt.% of lactic acid, citric acid, and / or a salt thereof; benzoic acid and / or a salt thereof; from about 0.1 to about 3 wt.% of ethoxylated fatty alcohol; and water, wherein the total amount of surfactant in the fabric care composition does not exceed about 3 wt.%, wherein all weight percentages are based on the total weight of the fabric care composition.

The present application belongs to the technical field of atomized liquid component design, and particularly relates to an atomized liquid, an atomizer and an aerosol generating device. The atomized liquid comprises, by weight percentage, nicotine 0.1-5%, benzoic acid 0.1-3%, lactic acid 0.1-3%, smoke agent 30-50%, essence 0.8-10%, additive 1-8%, and the rest is solvent. The addition of an appropriate amount of lactic acid in the benzoic acid nicotine salt atomized liquid has a significant effect on the improvement of carbon deposition, and the TPM is relatively stable and has a good taste. The addition of vanillin and its derivatives has a very obvious beneficial effect on the improvement of carbon deposition after the addition of lactic acid.

The invention relates to methods of inhibiting hair growth in a subject, the method comprises administering an inhibitor of lactic acid fermentation to the subject, wherein the inhibitor is selected from the group consisting of pyruvate dehydrogenase kinase inhibitor, desoxyrhapontigenin, a phosphofructokinases inhibitor, a thioredoxin-1 inhibitor, L- Asparaginase, a GLUT1 inhibitor, a glutaminase C inhibitor, a hexokinase inhibitor and an mTORCI and mTORC2 inhibitor. Also provided herein are compositions for inhibiting hair growth and methods of screening for inhibitors of hair growth.

The application provides a modified form of DEPTOR, DEPTOR K106 lactylation, as a biomarker in the preparation of a test agent for the preliminary evaluation or prediction of liver cancer. The application also provides a kit for quantitatively or semi-quantitatively detecting a protein, which contains an antibody capable of specifically binding to DEPTOR K106 lactylation. The application can more effectively preliminarily evaluate and predict whether a subject has a tumor by detecting the expression level of DEPTOR K106 lactylation. The application will help improve the diagnostic accuracy of liver cancer and provide an important basis for early treatment of patients. The kit of the application can be used for the diagnosis of early, medium and late liver cancer.

This invention discloses a lactate reactor capable of inhibiting intervertebral disc degeneration and its preparation method. The lactate reactor is an injectable gel microsphere loaded with lactate-catalyzing nanoparticles and matrix cell-derived factor SDF-1α. The lactate-catalyzing nanoparticles are mesoporous silica nanoparticles, whose mesopores are coated with lactate dehydrogenase, nicotinamide adenine dinucleotide, alanine aminotransferase, and glutamate, and whose surface is coated with an oxidized sodium alginate layer via a Schiff base reaction. This invention can efficiently convert pathological lactate in the nucleus pulposus microenvironment into alanine, which inhibits degeneration, while simultaneously recruiting stem cells to synergistically inhibit the process of intervertebral disc degeneration.

The application discloses a synthesis method of Amadori compound and belongs to the field of organic synthesis. The application uses lactic acid, glycerol and choline chloride to prepare a low eutectic solvent, which is used as a reaction system of the Amadori compound. The low eutectic solvent system has excellent solubility for reducing sugar and amino acid, does not need a cosolvent, has a uniform reaction system and high mass transfer efficiency. The components (choline chloride, glycerol and lactic acid) used are all natural biodegradable substances, and are non-toxic and non-residual. The subsequent NADES can be recovered by ethanol precipitation, and the recycling rate is more than 95%, and basically no three wastes are discharged.

This invention provides *Pediococcus lactis* SHI03 and its application in alleviating insulin resistance and type 2 diabetes, belonging to the field of microbial technology. This invention provides *Pediococcus lactis* SHI03, with accession number CCTCC No: M 20242686, and confirms that this strain possesses in vitro α-glucosidase inhibitory activity, exhibiting excellent probiotic and hypoglycemic effects. This invention further provides microbial products containing *Pediococcus lactis* SHI03, including *Pediococcus lactis* SHI03 fermentation broth, *Pediococcus lactis* SHI03 fermentation supernatant, and *Pediococcus lactis* SHI03 cells, and their applications in alleviating high-fat diet-induced insulin resistance and reducing fasting blood glucose in type 2 diabetic mice.

This invention discloses a honeysuckle cleansing essence care base material, its preparation method, and its application. The raw material components of the care base material are: honeysuckle flower extract 0.01-10.0%, lactobacillus fermentation product 0.01-10.0%, menthyl lactate 0.1-5.0%, propylene glycol 5.0-40.0%, ethylhexylglycerin 0.5-2.0%, squalane 0.01-0.15%, hydrogenated lecithin 0.5-1.5%, and the remainder being purified water. The components of this invention work synergistically to produce disposable hygiene products and washing and care products with antibacterial, anti-inflammatory, soothing, repairing, and deodorizing effects. It significantly alleviates symptoms such as heat, inflammation, itching, and stinging in the female vulva, strengthens the skin barrier function, and meets the demand for "comfort, antibacterial, and deodorizing" under the trend of consumption upgrading. At the same time, the preparation process is stable and controllable, suitable for large-scale production.

The present application relates to a preparation and application of a lactylation modified XLF protein and inhibition of XLF lactylation. The present application researches and finds that protein lactylation regulates the function of XLF in the NHEJ process by promoting the interaction of XLF and Ku80. Under the catalysis of GCN5 (lysine acetyltransferase 2A, KAT2A), XLF is lactylated to improve the efficiency of NHEJ and cause the chemotherapeutic resistance of colorectal cancer (CRC) cells. In addition, the inhibition of XLF lactylation can increase the sensitivity of CRC cells to chemotherapy and radiotherapy. The present application also obtains a polypeptide by design and screening, which can specifically inhibit the lactylation of XLF at K288, and has a synergistic effect on CRC when combined with 5-FU, and the polypeptide can promote the chemotherapeutic sensitivity of colorectal cancer.

Compositions, methods, and uses are contemplated in which a betalain-containing preparation is administered to a mammal to enhance athletic performance. Most preferably, the preparations are substantially nitrate free and acutely and transiently increase hematocrit, erythropoietin, adrenalin, and beta endorphin, while reducing serum lactate, serum lactate dehydrogenase, heart rate and a rate of perceived exertion.

Provided are methods for preventing or treating a chronic pain in a subject that includes administering an effective amount of a composition of Lactococcus lactis DSM 27109 to the subject.

This application discloses the application of HNRNPF K224 lactation modification as a target in the preparation of products for the diagnosis and / or treatment of pancreatic cancer, belonging to the field of precision oncology product technology. Examples of this application demonstrate that the lactation modification level of HNRNPF protein at site K224 is significantly higher in pancreatic cancer tissue than in adjacent normal tissue. The lactation modification level of lysine 224 in HNRNPF protein is positively correlated with the progression of pancreatic cancer. Constructing the HNRNPF K224R point mutant can significantly inhibit the proliferation of pancreatic cancer cells. Based on this, this application provides reagents for detecting HNRNPF K224 lactation levels, which can be used to prepare products for the diagnosis and / or treatment of pancreatic cancer, such as reagents for detecting or inhibiting this modification. This application provides new specific biomarkers and intervention strategies for the early diagnosis and targeted therapy of pancreatic cancer, and has significant meaning and application value.

A composition for treating hair loss and stimulating hair growth, the composition comprising polylactic acid (PLA) particles or derivatives thereof, in a pharmaceutically acceptable carrier; wherein the composition further comprises bacteriostatic or deionized water and at least one excipient; wherein the PLA particles or derivatives thereof are suspended in the carrier. Further disclosed is a composition comprising poly-L-lactic acid (PLLA) particles for use in a method of stimulating hair growth on a scalp of a subject, wherein the PLLA particles are suspended in a pharmaceutically acceptable carrier, wherein the composition comprises bacteriostatic or deionized water and at least one excipient, wherein the PLLA particles function as a pro-drug that degrades in situ to provide a sustained release of lactic acid to follicular cells.

This invention relates to the field of microorganisms or enzymes, and discloses a T-cell activation and expansion medium and its culture process. The culture process includes: inoculating isolated T cells into a basal medium containing IL-2 and culturing them; on the 4th day of culture, adding IL-7, IL-15, and a defined molar ratio of nicotinamide and N-acetyl-L-cysteine ​​to the system; calculating the metabolic quotient by monitoring changes in lactate and glucose concentrations in the supernatant; and triggering a feeding action based on the metabolic quotient. During the feeding stage, the supplementation ratio of nicotinamide and N-acetyl-L-cysteine ​​is adjusted according to the threshold of the metabolic quotient. This invention achieves a precise coupling between mitochondrial energy drive and oxidative damage quenching, thereby solving the technical contradiction of difficulty in balancing expansion efficiency and phenotypic maintenance, effectively blocking the late-stage metabolic exhaustion pathway and directionally enriching memory subpopulations.

The application belongs to the technical field of biological medicine, and particularly relates to application of phenylalanine lactate in preparation of medicines for distinguishing healthy people from hypertension patients and improving blood pressure of hypertension patients. The application discloses phenylalanine lactate, medicines for detecting phenylalanine lactate, and application of phenylalanine lactate as a marker in preparation of medicines for distinguishing healthy people from hypertension patients. The application provides application of phenylalanine lactate in preparation of medicines for preventing, improving or treating hypertension. Meanwhile, the application also provides a detection method of phenylalanine lactate, and improves accuracy of biological sample detection. The application can prevent, improve or treat hypertension by detecting content of phenylalanine lactate in a biological sample and supplementing phenylalanine lactate.

This invention relates to the technical field of tobacco leaf preservation, and particularly to a tobacco humectant, its preparation method, and its application. The tobacco humectant is formed by a eutectic reaction of a hydrogen bond donor and a hydrogen bond acceptor. The hydrogen bond acceptor includes at least one selected from betaine, urea, diammonium hydrogen phosphate, ammonium chloride, and ammonium acetate. The hydrogen bond donor includes at least one selected from sodium phytate, tartaric acid, itaconic acid, potassium lactate, and D-glucopyranose. This invention, by forming a eutectic solvent system and constructing a stable hydrogen bond network, enables the prepared tobacco humectant to possess excellent dual functions of hygroscopic absorption and water retention. When sprayed onto reconstituted tobacco leaves, it solves the problems of rapid moisture release and easy drying of reconstituted tobacco leaves, significantly improving their water-holding capacity. Simultaneously, through precise selection of hydrogen bond donors and acceptors, it further reduces the impact on the user's smoking experience.

Disclosed are a lactylated NBS1 protein and uses thereof. A lactylation site in this application is lysine at position 388 of NBS1 protein. Lactylation at K388 site of the NBS1 protein activates the DNA repair pathway and has multiple functions, including promoting radiotherapy and chemotherapy resistance in tumor cells and enhancing homologous recombination in DNA repair. By targeted inhibition of the lactylated NBS1 protein, tumor resistance to radiotherapy or chemotherapy can be reversed, providing a potential target for reversing tumor resistance to radiotherapy or chemotherapy.

This invention provides a stable and effective immune-enhancing extract of Lycium barbarum. The preparation method of the Lycium barbarum extract includes the following steps: (1) Fresh Lycium barbarum fruit is mixed with an organic acid aqueous solution of 1%~3% g / mL at a ratio of 2:1 g / mL and pulped. The organic acid is selected from citric acid, lactic acid, or malic acid. (2) The pulp is enzymatically inactivated and sterilized. (3) The pulp is filtered through a 200-mesh plate and frame filter. (4) The filtrate is enriched by macroporous resin and eluted sequentially with water and 60% v / v ethanol. The macroporous resin is selected from D101 and / or AB-8. The 60% v / v ethanol eluent is collected, concentrated at low temperature to remove alcohol, and the Lycium barbarum extract is obtained. This invention also provides a relatively unique preparation process for the extract. Studies have found that the amount of citric acid added in this invention has a significant effect on the immune-enhancing effect. When the concentration of the citric acid aqueous solution is 1%~3% g / mL, the immune-enhancing effect is significantly improved compared to not using citric acid or a higher concentration (4%).

The present invention discloses a heme iron – glycine chelated iron supplement preparation, belonging to the technical field of nutritional and pharmaceutical preparations. The preparation employs a four-source composite of heme iron, glycine chelated iron, ferrous gluconate, and ferrous lactate, enabling iron supplementation via heme receptor absorption, amino acid chelation pathways, and ionic diffusion. This design overcomes the limitations of single iron sources, including gastrointestinal irritation and low absorption of inorganic iron, dietary inhibition of conventional organic iron, and the high cost or slow onset of novel iron sources. The four iron sources act synergistically to reduce free iron ions and integrate multiple absorption pathways. As a result, gastrointestinal irritation is minimized, and the inhibitory effects of phytic acid, oxalic acid, and tannins are reduced, enabling stable and efficient intestinal absorption. The preparation achieves non-irritating, highly bioavailable, and sustained iron supplementation.

Certain aspects of the present disclosure relate generally to a method for identifying a risk of sepsis in a body of a patient. The method includes measuring lactate concentrations associated with the body over one or more time periods. The method further includes identifying the risk of sepsis based on the lactate concentrations.

This invention belongs to the field of personal care product technology, specifically relating to a male genital mousse wash containing PHMB and its preparation method. The wash uses polyhexamethylene biguanide hydrochloride (PHMB) as the core antibacterial agent, combined with cocoylpropyl betaine and sodium lauroyl sarcosinate as the cleansing surfactant system, compounded with sodium hyaluronate, panthenol, and dipotassium glycyrrhizate, supplemented with propylene glycol, glycerin, disodium EDTA, and phenoxyethanol. The pH is adjusted to 5.0–6.0 with L-lactic acid, and the remainder is water for injection. The preparation employs a low-temperature stepwise feeding process to obtain a weakly acidic mousse foam. The product exhibits an antibacterial rate of ≥99.99% against Escherichia coli, Staphylococcus aureus, and Candida albicans, is non-irritating to the skin, produces a dense and stable foam that is easy to rinse, and has good high and low temperature stability. It combines cleansing, antibacterial, and mucosal repair effects, solving the problems of traditional feminine hygiene products such as high irritation, easy allergy, and poor dosage form experience. It is suitable for daily cleaning and care of the male genitalia.

The present invention relates to a catalyst for dehydrogenation of glycerol and to a catalyst for dehydrogenation of glycerol, which includes a group 10 element on the periodic table as a catalytically active component and a composite metal oxide composed of zirconium (Zr) and cerium (Ce) as a catalyst support, and a manufacturing method thereof.

A fire-retardant topical formulation comprising glycerol and urea in a ratio of 1:1 to 1:30 is provided. The formulation may further comprise polyvinyl pyrrolidone and / or ethylhexylglycerin, and / or a barrier forming agent and / or a stabilising agent. The formulation may be a moisturiser, shampoo, conditioner, hair dye, sun cream, aftersun composition, emollient or medical composition. The formulation may be for use in treating a skin condition, such as eczema, dermatitis, psoriasis, elderly dry and itchy skin, ichthyosis, rash, or infection. The composition when transferred to a fabric suppresses the flammability of the fabric and is also capable of being removed from the fabric by washing. A preferred formulation comprises 1% phenoxyethanol, 10% urea, 10% sodium lactate (60% solution), 1% lactic acid, 1% glycerol, 3% ethylhexylglycerin, 2% polyacrylate crosspolymer-6, 0.5% polyvinylpyrrolidone and 71.5% water by weight. A fire-retardant topical formulation comprising 1% glycerol, 2% polyacrylate crosspolymer-6, 10% sodium lactate solution, 1% phenoxyethanol, 1% lactic acid, 3% ethylhexylglycerin and 0.5% polyvinylpyrrolidone by weight is also disclosed. [Fig: None]

Provided are a histone lactylation blocker and the use thereof in the treatment of tumors. The histone lactylation blocker has an amino acid sequence as shown in SEQ ID NO: 1, and exhibits the effect of blocking histone lactylation. Further disclosed are a polynucleotide encoding the histone lactylation blocker, a corresponding vector, host cell, pharmaceutical composition, composition, product combination, kit, etc., and the use thereof and a production method therefor. The histone lactylation blocker has an anti-tumor effect and exhibits a synergistic effect with immune checkpoint blockade therapy (such as an anti-PD-1 antibody).

This invention has discovered that the pathogenesis of kidney stones is accompanied by a significant increase in the lactation modification level of histidine at position 147 of ALDOB. Furthermore, when histidine at position 147 is mutated, the lactation modification at position 147 of the mutant amino acid disappears. In vivo experiments show that this mutation can significantly inhibit the accumulation of calcium oxalate crystals in mouse kidneys, preventing the occurrence of kidney stones. Based on this, this invention provides a novel agent and pathway for the prevention and treatment of kidney stones.